Shareholding disclosure

Michel Dreano

Declared position

9.99%

Threshold

Crossed upwards

Timeline

Published

10.11.2017

Transaction

06.11.2017

Transfer date

06.11.2017

Voting rights breakdown

Voting rights acquired9.99%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAHB800030

Beneficial owner

Michel Dreano

Declared address

Michel Dreano, 74160 Collonges sous Salève

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Michel Dreano

MindMaze Therapeutics Holding SA10.11.2017TAHB800030

Disclosure summary

Michel Dreano disclosed a holding in MindMaze Therapeutics Holding SA on the acquisition side, published by SIX Exchange Regulation on 10.11.2017, at 9.99% of voting rights. Notice category: Single shareholder.

Disclosed position

9.99%

Voting rights acquired

Voting rights acquired9.99%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Michel Dreano disclosed a holding in MindMaze Therapeutics Holding SA, published on 10.11.2017.

Publication date10.11.2017

Transaction date06.11.2017

Transfer date06.11.2017

Issuing companyMindMaze Therapeutics Holding SA

Beneficial ownerMichel Dreano

Declared addressMichel Dreano, 74160 Collonges sous Salève

CategorySingle shareholder

Voting rights acquired9.99%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAHB800030

Source: SIX Exchange Regulation · Publication date: 10.11.2017

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open